2018-Mar-31

MetrioPharm Investor Relations News QI 2018

 

Greetings from Dr. Wolfgang Brysch, CEO of MetrioPharm AG

Dear Shareholders

These are eventful days at MetrioPharm: Our current Phase II study was approved by the authorities at the end of 2017/beginning of 2018 and started on schedule a few weeks ago. In this larger clinical trial, we are testing the safety and efficacy of MP1032 in patients with psoriasis. Our goal is to confirm the good data from the Phase IIa exploratory study over a longer period of time and to determine the optimal dosing for MP1032.

MetrioPharm is following the progress of the study with great interest and we will keep you informed of all important progress: We expect first results (Topline Data) at the beginning of 2019.

On behalf of the entire team, I wish you all the best and relaxing days for the coming Easter season.

Sincerely yours

Dr. Wolfgang Brysch
Chief Executive Officer

 


First Patient First Dose

On March 6, 2018, the first patient in MetrioPharm's current Phase II clinical study was dosed. The Phase II study is being conducted in Germany and Poland as a multicenter, randomized, double-blind, placebo-controlled, twice-daily oral trial over 12 weeks. Psoriasis patients aged 18 to 70 years receive either MP1032 (150 mg or 300 mg) or placebo. Around 14 study centres in Germany and Poland will participate in this study. The primary objective is to evaluate the clinical efficacy and safety of MP1032 at different doses.


MetrioPharm Blog

In January, the MetrioPharm Blog was launched. Here you can find information about the current work of MetrioPharm. For example, a detailed background regarding the current Phase II study: https://blog.metriopharm.com


MetrioPharm in San Francisco, USA

From January 8-10, 2018, the J.P. Morgen Healthcare Conference took place again in San Francisco, USA. The conference is regarded as the world's largest networking event for companies in the healthcare sector. Dr. Wolfgang Brysch, CEO, and Felix Edler, Business Development, took this opportunity to meet with representatives of global and regional pharmaceutical companies in San Francisco to discuss possible partnerships.


MetrioPharm at Swiss Nordic Bio in Zurich, Switzerland

Swiss Nordic Bio in Zurich is a partnering and investor event at which Swiss and Nordic biotech start-ups, pharmaceutical companies and investors meet. On February 8, 2018, Dr. Wolfgang Brysch presented MetrioPharm AG to an interested audience and attended a series of one-on-one meetings to talk to investors and discuss opportunities for future partnerships.


Investor Talks with MetrioPharm AG in Monaco

On March 15, 2018, Dr. Wolfgang Brysch, CEO, and Eva Brysch, Investor Relations, presented MetrioPharm AG to potential investors in Monaco during the Investor Talks. The Investor Talks were organized by the Deutsche Börse Venture Network to provide a platform for non-listed companies to establish contacts with investors for pre-IPO financing rounds around the world.

 


Corporate Calendar of MetrioPharm AG in QII 2018

April 16, 2018: Investor Talks, Munich, Germany
The Investor Talks organized by the Deutsche Börse Venture Network will take place in Munich on April 16, 2018. MetrioPharm AG will be represented by Dr. Wolfgang Brysch, CEO, and Eva Brysch, Investor Relations, and will give a presentation to potential investors.

May 03, 2018: Swiss Biotech Day, Basel, Switzerland
MetrioPharm will be present at the Swiss Biotech Day in Basel on May 03, 2018. The Swiss Biotech Day serves the exchange between entrepreneurs and experts of the Swiss biotechnology industry. In addition, a matching between investors, pharmaceutical partners and biotechnology companies has been taking place since 2016.

June 04-07, 2018: BIO International Convention, Boston, USA
The BIO International Convention is organized by the Biotechnology Innovation Organization (BIO). It is the world's largest event for the biotechnology industry and attracts many big names in the healthcare sector, offers important networking and partnering opportunities, and provides insights and suggestions on the most important trends in the industry.

June 20, 2018: Annual General Meeting of MetrioPharm AG, Zurich, Switzerland
The Annual General Meeting of MetrioPharm AG is expected to take place on June 20, 2018 in Kloten (Zurich). We look forward to seeing you in large numbers. You will receive an invitation to the Annual General Meeting with the scheduled topics separately by post, provided that your shares are entered in our share register.

Please note that our shares are registered shares. This means that you may only exercise your voting rights if your shares are entered in our share register in your name or in the name of a proxy. If you are not sure whether your shares are registered, ask your bank or MetrioPharm. Please also check whether the number of registered shares is correct.

Your contacts at MetrioPharm are:

 MetrioPharm, Eva Brysch, Investor Relations Manager                        

 MetrioPharm, Sandra Meissner, Executive Assistant
Eva Brysch
Investor Relations Manager
Phone: +49-(0)30-3384-395-40
E-mail: invest@metriopharm.com
Sandra Meissner 
Executive Assistant
Phone: +49-(0)30-3384-395-22
E-mail: invest@metriopharm.com